Opendata, web and dolomites

TCRabX SIGNED

Structural basis for the therapeutic efficiency of optimal-affinity T cell receptors

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TCRabX project word cloud

Explore the words cloud of the TCRabX project. It provides you a very rough idea of what is the project "TCRabX" about.

australia    therapeutic    newly    melbourne    chains    innovative    mice    recognizing    molecules    health    alpha    delay    powerful    cancer    complementarity    dimensional    isolated    specificity    chemotherapy    structures    antigens    13    tumour    immunotherapy    surgery    topologies    analysed    trials    diverse    radiation    beta    class    exceptional    lymphocytes    helps    tcrs    rates    regions    histocompatibility    cdr    receptor    human    humanized    patient    connects    made    cognate    therapeutically    middle    germany    regression    optimal    therapy    peptide    incidence    naturally    pmhc    aged    docking    genes    gene    affinity    begin    repertoire    berlin    points    ray    biology    negative    benefit    uncovered    complexed    worldwide    respectively    immunology    types    contact    citizens    peripheral    elderly    date    macromolecules    3d    demographic    mhc    cell    tcrabx    efficient    tcr    hugely    biological    cells    determined    population    blood    cdrs    world    identification    loaded    form    ageing    supporting    crystallography    biomedical    treatment    people    clinical    transfer    structural    mediated    tool    interdisciplinary    self    alternative    antigen   

Project "TCRabX" data sheet

The following table provides information about the project.

Coordinator
CHARITE - UNIVERSITAETSMEDIZIN BERLIN 

Organization address
address: Chariteplatz 1
city: BERLIN
postcode: 10117
website: www.charite.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 264˙110 €
 EC max contribution 264˙110 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-GF
 Starting year 2019
 Duration (year-month-day) from 2019-08-01   to  2022-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    CHARITE - UNIVERSITAETSMEDIZIN BERLIN DE (BERLIN) coordinator 264˙110.00
2    MONASH UNIVERSITY AU (VICTORIA) partner 0.00

Map

 Project objective

Demographic change includes population ageing, and incidence rates begin to increase for many types of cancer in middle-aged and elderly people. Traditional cancer treatment includes surgery, chemotherapy, and radiation therapy, while tumour immunotherapy by T cell receptor (TCR) gene transfer represents an alternative form of treatment. The transfer of tumour-specific TCR genes into patient’s peripheral blood lymphocytes targets cancer specifically and effectively. But while patient-derived low-affinity TCRs do not show therapeutic activity, optimal-affinity TCRs, as isolated from newly-generated antigen-negative humanized mice with a diverse human TCR repertoire, can effectively delay tumour regression. X-ray crystallography is a powerful tool of structural biology, which helps researchers to identify the three-dimensional (3D) structures of biological macromolecules such as TCRs complexed to their cognate peptide-loaded major histocompatibility complex (pMHC) molecules. Recent research uncovered the docking topologies of naturally selected TCRs, but therapeutically efficient optimal-affinity TCRs recognizing tumour-associated self-antigens, have not been analysed to date. The exceptional specificity of TCRs is determined by three complementarity-determining regions (CDRs) of the TCR alpha- and beta-chains. Biomedical research on TCR gene therapy and design of future clinical trials will hugely benefit from the identification of CDR-mediated contact points made between therapeutic TCRs and the pMHC on their target cells. TCRabX is an interdisciplinary research project investigating the 3D structures of 13 TCRs complexed to MHC-I or MHC-II, respectively. It connects innovative clinical immunology research in Berlin/Germany and world-class structural biology research in Melbourne/Australia. The proposed research will enhance the health and well-being of citizens in Europe and worldwide by supporting the advancement of cancer immunotherapy approaches.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TCRABX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TCRABX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

MathematicsAnalogies (2019)

Mathematics Analogies

Read More  

RegARcis (2020)

Role of the SWI/SNF complex in the Androgen Receptor cistrome regulation

Read More